Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 208-932-1 | CAS number: 547-66-0
Endpoint summary
Administrative data
Description of key information
The LD50 of the test item Magnesium oxalate is higher than 2000 mg/ kg body weight by oral route in the rat.
The LD50 of the test item Magnesium oxalate is higher than 2000 mg/ kg body weight by dermal route in the rat.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 17/07/2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Remarks:
- A temperature higher than 25°C was registered on 17 and 18 April 2018. The maximum value measured was 26°C. This deviation is considered as without impact on the conclusion of the study.
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and batch No.of test material: Bernardy SAS, Batch No 1601762
- Production date of the batch : 29 September 2016
- Expiration date of the batch: 29 September 2019
- Purity test date: 30/09/2016
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: room temperature in opaque plastic flask
- Stability under test conditions: stable
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: No (Olive oil was added for the oral administration)
FORM AS APPLIED IN THE TEST
White solid powder - Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: supplied by Elevage JANVIER LABS (53940 Le Genest St Isle – France)
- Females nulliparous and non-pregnant: yes
- Age at study initiation: At the beginning of the study, the animals were 8 or 9 weeks old.
- Weight at study initiation: Mean = 199.3grams (standard deviation 11.2 grams)
- Fasting period before study: Food was removed on day 1 and then redistributed 4 hours after the test item administration.
- Housing: Healthy female rats were housed by group of three in solid-bottomed clear polycarbonate cages with a stainless steel mesh lid. Each cage contains sawdust bedding which was changed at least 2 times a week. Each cage was installed in conventional air conditioned animal husbandry.
- Diet : ad libitum
- Water : ad libitum
- Acclimation period: acclimatization period of at least five days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): ranges of 19°C to 25°C
- Humidity (%): ranges of 30% to 70%,
- Air changes (per hr): at least ten changes per hour
- Photoperiod (hrs dark / hrs light): twelve hours continuous light (07.00 to 19.00) and twelve hours darkness
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: In the first and second steps of the study, 0.3041 g and 0.3005 g of the test item were weighed and olive oil was added to two 10mL volumetric flasks. In the third and fourth steps of the study, 2.0066 g and 2.0004 g of the test item were weighed and olive oil was added to two 10 mL volumetric flasks.
- Amount of vehicle: olive oil was added and each preparation was administered under a volume of 10 mL/kg body weight
- Justification for choice of vehicle: Olive oil was chosen as it produced the most suitable formulation at the requested concentration.
MAXIMUM DOSE VOLUME APPLIED:
The first tested dose was 300 mg/kg body weight. The second dose was 2000 mg/kg body weight.
DOSAGE PREPARATION:
Olive oil was added and each preparation was administered under a volume of 10 mL/kg body weight using a suitable syringe graduated fitted with an oesophageal metal canula. Just before the administration, the preparations were stirred by vortex to obtain yellow thin homogeneous solutions.
CLASS METHOD
- Rationale for the selection of the starting dose: The starting dose was determined according to the toxicological information publicly available on analogue substances. - Doses:
- Two doses were tested : 300 mg/kg body weight and 2000 mg/kg body weight.
- No. of animals per sex per dose:
- 3 female per step (2 steps per dose)
- Control animals:
- yes
- Remarks:
- Three animals, received the control item olive oil. Nothing to report. Animal normal (3/3)
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: The animals were weighed on day D0 (just before administering the test item) then on day 2, day 7, and day 14.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, macroscopic examinations of organs in the necropsy. - Preliminary study:
- No preliminary study. The starting dose was determined according to the toxicological information publicly available on analogue substances.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No effect observed.
- Clinical signs:
- No effect observed.
- Body weight:
- No effect observed.
- Gross pathology:
- No effect observed.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The LD50 of the test item Magnesium oxalate is higher than 2000 mg/ kg body weight by oral route in the rat.
In accordance with the O.E.C.D. Test Guideline No. 423, the LD50 cut-off of the test item may be considered to be higher than 5000 mg/ kg body weight by oral route in the rat.
The test item Magnesium oxalate does not have to be classified in accordance with the Regulation EC No. 1272/2008 on classification, labelling and packaging of substances and mixtures.
No signal word or hazard statement is required. - Executive summary:
The test item Magnesium oxalate was administered to a group of 6 female Sprague Dawley rats at the dose of 300 mg/kg body weight and then to a group of 6 female Sprague Dawley rats at the dose of 2000 mg/kg body weight. The experimental protocol was established according to the official method as defined in the O.E.C.D. Test Guideline No. 423 dated December 17th, 2001 and the test method B.1tris of the Council regulation No. 440/2008.
No mortality was noted in the animals treated at the dose of 300 mg/kg body weight. No clinical signs related to the administration of the test item were observed during the study. The body weight evolution of the animals remained normal during the study. The macroscopic examination of the animals at the end of the study did not reveal treatment related changes.
No mortality was noted in the animals treated at the dose of 2000 mg/kg body weight. No clinical signs related to the administration of the test item were observed during the study. The body weight evolution of the animals remained normal during the study. The macroscopic examination of the animals at the end of the study did not reveal treatment related changes.
In conclusion, the LD50 of the test item Magnesium oxalate is higher than 2000 mg/ kg body weight by oral route in the rat. In accordance with the O.E.C.D. Test Guideline No. 423, the LD50 cut-off of the test item may be considered to be higher than 5000 mg/ kg body weight by oral route in the rat. The test item Magnesium oxalate does not have to be classified in accordance with the Regulation EC No. 1272/2008 on classification, labelling and packaging of substances and mixtures. No signal word or hazard statement is required.
Reference
Application: 300 mg/kg body weight (oral route)
Table 1
Observations |
Females |
Females |
||||
T0 + 30 minutes T0 + 1 hour T0 + 3 hours T0 + 4hours |
Rf 2467 |
Rf 2468 |
Rf 2469 |
Rf 2470 |
Rf 2471 |
Rf 2472 |
Spontaneous activity |
N |
N |
N |
N |
N |
N |
Preyer’s reflex (noise) |
N |
N |
N |
N |
N |
N |
Respiratory rate |
N |
N |
N |
N |
N |
N |
Convulsion |
N |
N |
N |
N |
N |
N |
Tremors |
N |
N |
N |
N |
N |
N |
Body temperature |
N |
N |
N |
N |
N |
N |
Muscle tone |
N |
N |
N |
N |
N |
N |
Palpebral opening |
N |
N |
N |
N |
N |
N |
Pupil appearance |
N |
N |
N |
N |
N |
N |
Salivation |
N |
N |
N |
N |
N |
N |
Lachrymation |
N |
N |
N |
N |
N |
N |
Righting reflex |
N |
N |
N |
N |
N |
N |
Back hair appearance |
N |
N |
N |
N |
N |
N |
MORTALITY |
0 |
0 |
0 |
0 |
0 |
0 |
Remarks |
None |
None |
||||
Table 2
Observations |
Females |
Females |
||||
T0 + 30 minutes T0 + 1 hour T0 + 3 hours T0 + 4hours |
Rf 2467 |
Rf 2468 |
Rf 2469 |
Rf 2470 |
Rf 2471 |
Rf 2472 |
Spontaneous activity |
N |
N |
N |
N |
N |
N |
Preyer’s reflex (noise) |
N |
N |
N |
N |
N |
N |
Respiratory rate |
N |
N |
N |
N |
N |
N |
Convulsion |
N |
N |
N |
N |
N |
N |
Tremors |
N |
N |
N |
N |
N |
N |
Body temperature |
N |
N |
N |
N |
N |
N |
Muscle tone |
N |
N |
N |
N |
N |
N |
Palpebral opening |
N |
N |
N |
N |
N |
N |
Pupil appearance |
N |
N |
N |
N |
N |
N |
Salivation |
N |
N |
N |
N |
N |
N |
Lachrymation |
N |
N |
N |
N |
N |
N |
Righting reflex |
N |
N |
N |
N |
N |
N |
Back hair appearance |
N |
N |
N |
N |
N |
N |
MORTALITY |
0 |
0 |
0 |
0 |
0 |
0 |
Remarks |
None |
None |
||||
Application: 2000 mg/kg body weight (oral route)
Table 3
Observations |
Females |
Females |
||||
T0 + 30 minutes T0 + 1 hour T0 + 3 hours T0 + 4hours |
Rf 2476 |
Rf 2477 |
Rf 2478 |
Rf 2487 |
Rf 2488 |
Rf 2489 |
Spontaneous activity |
N |
N |
N |
N |
N |
N |
Preyer’s reflex (noise) |
N |
N |
N |
N |
N |
N |
Respiratory rate |
N |
N |
N |
N |
N |
N |
Convulsion |
N |
N |
N |
N |
N |
N |
Tremors |
N |
N |
N |
N |
N |
N |
Body temperature |
N |
N |
N |
N |
N |
N |
Muscle tone |
N |
N |
N |
N |
N |
N |
Palpebral opening |
N |
N |
N |
N |
N |
N |
Pupil appearance |
N |
N |
N |
N |
N |
N |
Salivation |
N |
N |
N |
N |
N |
N |
Lachrymation |
N |
N |
N |
N |
N |
N |
Righting reflex |
N |
N |
N |
N |
N |
N |
Back hair appearance |
N |
N |
N |
N |
N |
N |
MORTALITY |
0 |
0 |
0 |
0 |
0 |
0 |
Remarks |
None |
None |
||||
Table 4
Observations |
Females |
Females |
||||
T0 + 30 minutes T0 + 1 hour T0 + 3 hours T0 + 4hours |
Rf 2476 |
Rf 2477 |
Rf 2478 |
Rf 2487 |
Rf 2488 |
Rf 2489 |
Spontaneous activity |
N |
N |
N |
N |
N |
N |
Preyer’s reflex (noise) |
N |
N |
N |
N |
N |
N |
Respiratory rate |
N |
N |
N |
N |
N |
N |
Convulsion |
N |
N |
N |
N |
N |
N |
Tremors |
N |
N |
N |
N |
N |
N |
Body temperature |
N |
N |
N |
N |
N |
N |
Muscle tone |
N |
N |
N |
N |
N |
N |
Palpebral opening |
N |
N |
N |
N |
N |
N |
Pupil appearance |
N |
N |
N |
N |
N |
N |
Salivation |
N |
N |
N |
N |
N |
N |
Lachrymation |
N |
N |
N |
N |
N |
N |
Righting reflex |
N |
N |
N |
N |
N |
N |
Back hair appearance |
N |
N |
N |
N |
N |
N |
MORTALITY |
0 |
0 |
0 |
0 |
0 |
0 |
Remarks |
None |
None |
||||
Body weight and weight gain in grams
Table 5
Females |
D0 |
D2 |
D2-D0 |
D7 |
D7-D0 |
D14 |
D14-D0 |
Rf 2467 |
189 |
208 |
19 |
226 |
37 |
245 |
56 |
Rf 2468 |
206 |
224 |
18 |
234 |
28 |
265 |
59 |
Rf 2469 |
185 |
209 |
24 |
231 |
46 |
265 |
80 |
Rf 2470 |
196 |
220 |
24 |
229 |
33 |
259 |
63 |
Rf 2471 |
214 |
231 |
17 |
252 |
38 |
274 |
60 |
Rf 2472 |
206 |
209 |
3 |
240 |
34 |
281 |
75 |
MEAN |
199.3 |
216.8 |
17.5 |
235.3 |
36.0 |
264.8 |
65.5 |
Standard deviation |
11.2 |
9.6 |
7.7 |
9.5 |
6.0 |
12.4 |
9.7 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- the study does not need to be conducted because exposure of humans via inhalation is not likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size
- Justification for type of information:
- JUSTIFICATION FOR DATA WAIVING
According to the §8.5.2, column 2 of the annex VIII of REACh, testing is not appropriate for inhalation route since dermal exposure to the substance is more likely and acute toxicity data by dermal route is provided. - Reason / purpose for cross-reference:
- data waiving: supporting information
Reference
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 25/07/2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- Remarks:
- A temperature higher than 25°C was registered. The max. value measured was 26°C. A temperature lower than 19°C was registered. The min. value measured was 17°C. This deviation is considered as without impact on the conclusion of the study.
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and batch No.of test material: Beranrdy SAS, Batch No 1601762
- Production date of the batch : 29 September 2016
- Expiration date of the batch: 29 September 2019
- Purity test date: 30/09/2016
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: room temperature in opaque plastic flask
- Stability under test conditions: stable
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: paraffin oil was added just before administration
FORM AS APPLIED IN THE TEST
White solid powder - Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: supplied by Elevage JANVIER LABS (53940 Le Genest St Isle – France)
- Females nulliparous and non-pregnant: yes
- Age at study initiation: 8 weeks old
- Weight at study initiation: mean = 215.7 (standard deviation = 16.3)
- Housing: The rats were kept in solid-bottomed clear polycarbonate cages with a stainless steel mesh lid. Each cage contains dust free weed shavings which were changed at least 2 times a week. Each cage was installed in conventional air conditioned animal husbandry.
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: at least five days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): target ranges of 19°C to 25°C
- Humidity (%): target ranges of 30% to 70%
- Air changes (per hr): at least ten changes cycles per hour
- Photoperiod (hrs dark / hrs light): twelve hours continuous light (07.00 to 19.00) and twelve hours darkness
- Type of coverage:
- semiocclusive
- Vehicle:
- paraffin oil
- Details on dermal exposure:
- TEST SITE
- Area of exposure: fur was removed from the dorsal area of the trunk of the test animal by clipping
- % coverage: At least 10 per cent of the body surface area was clear for the application of the test item.
REMOVAL OF TEST SUBSTANCE
- Washing: The treated area was rinse with paraffin oil.
- Time after start of exposure: After 24-hour exposure period, the gauze dressings were removed and the treated area was rinse with paraffin oil.
TEST MATERIAL
- Amount applied: In view to obtain a solution at 2000 mg/kg, 2.0015 g of the test item were weighed and paraffin oil was added to ta 10 mL volumetric flask.
- Constant volume or concentration used: yes
VEHICLE
The test item was used as supplied in the study. Paraffin oil was chosen as it produced the most suitable formulation at the requested concentration. - Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg body weight administered under a volume of 10 mL/kg body weight
- No. of animals per sex per dose:
- Range-finding study: 1 female rat Rf2464 treated at 2000 mg/kg.
Main study : 2 female rats Rf2465 & Rf2466 treated at 2000 mg/kg - Control animals:
- not required
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality occurred during the study.
- Clinical signs:
- No systemic clinical sign related to the administration of the test item was observed.
- Body weight:
- The body weight evolution of the animals remained normal throughout the study.
- Gross pathology:
- The macroscopic examination of the animals at the end of the study did not reveal treatment-related changes.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The LD50 of the test item Magnesium oxalate is higher than 2000 mg/ kg body weight by dermal route in the rat.
The test item Magnesium oxalate does not have to be classified in accordance with the Regulation EC No. 1272/2008 on classification, labelling and packaging of substances and mixtures.
No signal word or hazard statement is required. - Executive summary:
The test item Magnesium oxalate was applied, as supplied, onto the intact skin of 3 female Sprague Dawley rats at the single dose of 2000 mg/ kg body weight. The experimental protocol was established on the basis of the method as defined in the O.E.C.D. Test Guideline No. 402 dated October 9th, 2017.
No mortality occurred during the study. No systemic clinical sign related to the administration of the test item was observed. The body weight evolution of the animals remained normal throughout the study. The macroscopic examination of the animals at the end of the study did not reveal treatment-related changes.
In conclusion, the LD50 of the test item Magnesium oxalate is higher than 2000 mg/ kg body weight by dermal route in the rat. The test item Magnesium oxalate does not have to be classified in accordance with the Regulation EC No. 1272/2008 on classification, labelling and packaging of substances and mixtures. No signal word or hazard statement is required.
Reference
Clinical observations
Rf2464 |
TO + 30min |
T0 + 3hours |
T0 + 5hours |
D1 |
D2 |
D3 |
D4 |
D5 |
D6 |
D7 |
D8 |
D9 |
D10 |
D11 |
D12 |
D13 |
D14 |
Spontaneous activity |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Preyer’s reflex (noise) |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Respiratory rate |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Convulsion |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Tremors |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Body temperature |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Muscle tone |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Palpebral opening |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Pupil appearance |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Salivation |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Lachrymation |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Righting reflex |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Treatment site |
|
|
|
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
MORTALITY |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Remarks |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rf2465 Rf2466 |
TO + 30min |
T0 + 3hours |
T0 + 5hours |
D1 |
D2 |
D3 |
D4 |
D5 |
D6 |
D7 |
D8 |
D9 |
D10 |
D11 |
D12 |
D13 |
D14 |
Spontaneous activity |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Preyer’s reflex (noise) |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Respiratory rate |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Convulsion |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Tremors |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Body temperature |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Muscle tone |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Palpebral opening |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Pupil appearance |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Salivation |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Lachrymation |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Righting reflex |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Treatment site |
|
|
|
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
MORTALITY |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Remarks |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Body weight and weight gain in grams
FEMALES |
D0 |
D2 |
D2-D0 |
D7 |
D7-D0 |
D14 |
D14-D0 |
Rf 2464 |
198 |
204 |
6 |
242 |
44 |
258 |
60 |
Rf 2465 |
230 |
231 |
1 |
269 |
39 |
284 |
54 |
Rf 2466 |
219 |
226 |
7 |
266 |
47 |
289 |
70 |
MEAN Standard deviation |
215.7 16.3 |
220.3 14.4 |
4.7 3.2 |
259.0 14.8 |
43.3 4.0 |
277.0 16.6 |
61.3 8.1 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
Justification for classification or non-classification
No adverse effect is observed at the highest dose tested (2000 mg/ kg body weight for oral and dermal routes), consequently no classification is needed. Nevertheless, existing harmonised classification (Index Number 607-007-00-3) for “salts of oxalic acid with the exception of those specified elsewhere in this Annex” should apply. Consequently, the substance is classified as Acute Tox. 4 (H302) for oral route and Acute Tox. 4 (H312) for dermal route.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
